Brazil Contradicts Bharat Biotech Claim On Emergency Approval For Covaxin

Controversy over a $324 million deal between Brazil and Bharat Biotech - for the import of 20 million doses of the 'made-in-India' COVID-19 vaccine Covaxin - continues to grow, with reports from the South American country saying its national health regulatory authority - ANVISA - had never actually granted the Hyderabad-based manufacturer an EUA (emergency use application).

About Us: NDTV brings you unbiased and comprehensive coverage of news and entertainment programmes in India and abroad. NDTV delivers reliable information across all platforms: TV, Internet and Mobile.

Subscribe to our channels:
NDTV: https://www.youtube.com/user/ndtv?sub_confirmation=1
NDTV India (Hindi News): https://www.youtube.com/user/ndtvindia?sub_confirmation=1

Follow us on Social Media:
Like us on Facebook: https://www.facebook.com/ndtv/
Follow us on Twitter: https://twitter.com/ndtv/
Follow us on Instagram: https://www.instagram.com/ndtv/
Join NDTV on Telegram Messenger: https://t.me/NDTVbot/?start=hi

Follow us on Google News for Breaking and Latest News Updates:
NDTV: https://bit.ly/3e5ngbP
NDTV India (Hindi News): https://bit.ly/3mNVwMY

Download NDTV Mobile Apps:
http://www.ndtv.com/page/apps

Watch More Videos:
http://www.ndtv.com/video?yt

#BreakingNews #LatestNews #TodayNews #PoliticalNews #News